Skip to main content
$7.60 -0.10 (-1.30%) At close · Jul 28
Market Cap
$472.01M
Shares
61.98M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.60 Open$7.55 Day$7.35–7.66 52W$3.76–9.12 Avg vol 30d1.7M Short int3.3M · 5.3% float · 2.9d Short vol37% DataJan 2020–Jul 2026

Up next

FQ2-27 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.2 · elevated Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +25%
above
Price vs 50-day avg +37%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 72%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +10%
trailing
6-month return +14%
trailing
YTD return −7%
this year
Relative strength +7%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow Accumulating
18 of 82 funds reported for Jun 30 · net +17.5K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.25% of float · ▲ +8.7% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
82 holders — near 1-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −56%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+25% Bullish
Price vs 50-day avg
+37% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
72% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $6 — 200d above 50d
Institutional flow Accumulating
18 of 82 funds reported for Jun 30 · net +17.5K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.25% of float · ▲ +8.7% MoM · 2.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
82 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $4 Now $8 · 72% 52-wk high $9
vs 200-day avg +25% vs 50-day avg +37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HELP
Cybin Inc.
this stock
$472.01M -7.1% 5.3%
ONC
BeOne Medicines Ltd.
$477.60B +7.3% +22179.2% 971.9 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$124.46B +8.2% +46.2% 29.1 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
$72.88B -9.8% +20.8% 17.0 3.3%
ARGX
Argenx SE
$54.57B +3.7% 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
85
% held
40.0%
Reported
18 of 82
Top holder
Venrock Adviser, LLC
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Rising
Shares short
3.3M
Days to cover
2.9d
Change
+261.5K sh
View
Short Volume
Short vol %
37%
As of
Jul 28, 2026
Short Total
View
Fails to Deliver
FTD shares
11.7K
Value
$80.3K
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
61.2%
Week of
May 4, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 21, 2026
This year
24
View
Exempt Offerings
Offering
Indefinite
Filed
Jul 16, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 15, 2026
View

Performance

5D 20D 120D MTD YTD
HELP -6.2% +10.5% +14.5% +15.0% -7.1%
SPY -1.0% 0.0% +7.4% -0.8% +8.6%
vs SPY -5.2% +10.5% +7.0% +15.8% -15.7%
Key facts CIK 1833141 CUSIP 23256X407 13F (30d) 18 filings 18 filers Visit website Investor relations